ECOR - エレクトロコア （electroCore Inc.） エレクトロコアECORのチャート
ECORの企業情報
| symbol | ECOR |
|---|---|
| 会社名 | ElectroCore Inc （エレクトロコア） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Electromedical_Electrotherapeutic Apparatus |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | 事業概要 ElectroCore Inc. formerly ElectroCore LLC is a commercial-stage bioelectronic medicine healthcare company. The Company is engaged in developing non-invasive vagus nerve stimulation (nVNS) therapy for the treatment of multiple conditions in neurology psychiatry gastroenterology and respiratory fields. The Company's gammaCore is a simple-to-use hand-held device that provides non-invasive dispensing therapy which stimulates the cervical branch of the vagus nerve. The gammaCore is a non-drug treatment for adults who suffer from episodic cluster and migraine pain. The Company's target is the treatment of primary headaches (migraine and cluster headache) and the associated chronic co-morbidities of gastric motility psychiatric sleep and pain disorders. エレクトロコアは米国のバイオエレクトロニクス企業。主に神経系疾患やリウマチなどの治療のために、非侵襲的な迷走神経刺激法の開発に従事する。同社は成人の偏頭痛およびエピソ―ドクラスタ―頭痛の急性疼痛の治療のために、処方箋のみの迷走神経刺激法のgammaCore(ガンマコア)を開発する。本社所在地はニュ―ジャ―ジ―州ベ―スキング・リッジ。 electrocore is, a us based electroceutical healthcare company, which is developing a range of non-invasive vagus nerve stimulation (nvns) patient administered therapies for the treatment of multiple conditions in neurology, psychiatry, gastroenterology and other fields. initial focus is on primary headache (migraine and cluster headache), with trials continuing in epilepsy, gastric motility disorders, depression and anxiety. electrocore, which was founded in 2005, has more than 30 employees and full time consultants with offices in the us (head office), germany (german and european head office), uk, italy, australia, and canada. |
| 本社所在地 | 150 Allen Road Suite 201 Basking Ridge NJ 07920 USA |
| 代表者氏名 | J.P. Errico J.P.エリコ |
| 代表者役職名 | Chairman of the Board Co-Founder Principal Investor and Chief Science_Strategy Officer |
| 電話番号 | +1 973-290-0097 |
| 設立年月日 | 38596 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2018年 |
| 従業員数 | 64人 |
| url | www.electrocore.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ecor |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -38.75351 |
| 終値（lastsale） | 13.28 |
| 時価総額（marketcap） | 391096451.52 |
| 時価総額 | 時価総額（百万ドル） 386.08990 |
| 売上高 | 売上高（百万ドル） 0.99239 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 290.26335 |
| 当期純利益 | 当期純利益（百万ドル） -45.14816 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 electroCore Inc. revenues increased 62% to $474K. Net loss increased 52% to $27.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Selling general and administrative increase from $7.9M to $18.8M (expense) Research and development increase of 48% to $6.7M (expense). |
ECORのテクニカル分析
ECORのニュース
electroCore Announces Departure of JP Errico from Board 2023/05/26 20:03:02 Investing.com
https://www.investing.com/news/assorted/electrocore-announces-departure-of-jp-errico-from-board-432SI-3092325
electroCore to Participate at 13th Annual LD Micro Invitational XIII 2023/05/23 12:00:00 Wallstreet:Online
ROCKAWAY, N.J., May 23, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR) a commercial-stage bioelectronic medicine and wellness company, today announced that electroCore’s Chief Executive Officer, Dan Goldberger, will present at the 13th Annual LD Micro Invitational XIII in Los Angeles, California from June 6-8, 2023. LD Micro Invitational XIII: Date: Tuesday,
electroCore, Inc. (ECOR) Q1 2023 Earnings Call Transcript 2023/05/04 03:41:06 Seeking Alpha
electroCore, Inc. (NASDAQ:NASDAQ:ECOR) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ETCompany ParticipantsNicole Jones - IRDan Goldberger - Chief Executive OfficerBrian Posner -…
electroCore: Q1 Earnings Insights 2023/05/03 20:05:18 Benzinga
electroCore (NASDAQ: ECOR ) reported its Q1 earnings results on Wednesday, May 3, 2023 at 04:00 PM. Here''s what investors need to know about the announcement. Earnings electroCore missed estimated earnings by 24.0%, reporting an EPS of $-1.24 versus an … Full story available on Benzinga.com
electroCore Announces First Quarter 2023 Financial Results 2023/05/03 20:01:00 GlobeNewswire
Record first quarter 2023 net sales of $2.8 million, approximately 46% over first quarter 2022
The electroCore Inc. (ECOR) had a good session last reading, didn’t it? 2023/01/03 16:54:00 US Post News
A share of electroCore Inc. (NASDAQ:ECOR) closed at $0.26 per share on Friday, down from $0.29 day before. While electroCore Inc. has underperformed by -9.98%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ECOR fell by -57.21%, with highs and lows ranging from $0.98 to $0.19, […]
electroCore Inc. (NASDAQ: ECOR) Shares Have Been Down About -55.92% Year-To-Date Since The Beginning Of 2022 2022/12/31 12:30:00 Marketing Sentinel
During the last session, electroCore Inc. (NASDAQ:ECOR)’s traded shares were 0.68 million, with the beta value of the company hitting 0.87. At the end of the trading day, the stock’s price was $0.26, reflecting an intraday loss of -9.98% or -$0.03. The 52-week high for the ECOR share is $0.98, that puts it down -276.92 … electroCore Inc. (NASDAQ: ECOR) Shares Have Been Down About -55.92% Year-To-Date Since The Beginning Of 2022 Read More »
electroCore launches new wellness product offering for stress, anxiety and sleep 2022/12/20 13:29:58 Seeking Alpha
electroCore (ECOR) launches a new wellness product offering called Truvaga for customers residing in the United States
electroCore, Inc. Launches New Wellness Product Offering for Stress, Anxiety and Sleep, Truvaga 2022/12/20 13:00:00 Wallstreet:Online
ROCKAWAY, N.J., Dec. 20, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic company, today announced the launch of a new wellness product offering called TruvagaTM for customers residing in the United States. The new wellness product is offered through our new ecommerce site, www.truvaga.com, and promotes general wellbeing. Truvaga is a handheld
electroCore, Inc. Launches New Wellness Product Offering for Stress, Anxiety and Sleep, Truvaga™ 2022/12/20 13:00:00 GlobeNewswire
ROCKAWAY, N.J., Dec. 20, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic company, today announced the launch of a new wellness product offering called Truvaga TM for customers residing in the United States. The new wellness product is offered through our new ecommerce site, www.truvaga.com, and promotes general wellbeing.
gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Selected for Department of Defense Biotech Optimized for Operational Solutions and Tactics (BOOST) Program 2022/04/19 12:00:00 Wallstreet:Online
ROCKAWAY, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore nVNS has been selected for further study under the United States Department of Defense Biotech Optimized for Operational Solutions and Tactics (BOOST) program. The program, which is expected to run through September 2023,
electroCore rises 4% PM as 1Q22 revenue expected above the consensus 2022/04/12 12:25:35 Seeking Alpha
electroCore (ECOR) climbed 4% PM as 1Q22 revenue from product sales expected to be ~$1.9M vs consensus of $1.74M, an 27% increase Q/Q and 60% growth Y/Y. The Company expects to…
ElectroCore enters into an exclusive license agreement with Teijin for Japan territory 2022/04/05 12:50:30 Seeking Alpha
ElectroCore (ECOR) up 2% PM on agreement with a Japan based global conglomerate Teijin Limited to license certain exclusive rights to its non-invasive vagus nerve stimulation…
Vagus Nerve Stimulators Market is Expected to Witness Positive Growth With A CAGR of 9.06% During the Study Period (2018-26) 2022/03/14 17:00:00 Benzinga
New York, USA, March 14, 2022 (GLOBE NEWSWIRE) -- Vagus Nerve Stimulators Market is Expected to Witness Positive Growth With A CAGR of 9.06% During the Study Period (2018-26) As per DelveInsight analysis, the Vagus Nerve Stimulators Market is witnessing a surge primarily due to the rising prevalence of neurological diseases, the increasing popularity of VNS therapy as an alternative or even conjunctive treatment in cases where drug resistance develops, growing research in studying the effects of VNS on other indications, technological advancements leading to the development of new products such as non-invasive Vagus Nerve Stimulation devices, and others. DelveInsight''s Vagus Nerve Stimulators Market Insights report provides the current and forecast market, upcoming device innovation, individual leading companies market shares, challenges, market drivers, barriers, and trends, and key Vagus Nerve Stimulators companies in the market. Key Takeaways from the Global Vagus Nerve Stimulators Market According to DelveInsight analysis, North America is anticipated to dominate the global Vagus Nerve Stimulators market during the forecast period.
Boom Or Bust? Where Will electroCore Inc. (NASDAQ: ECOR) Stock Go Next? 2022/03/12 12:30:00 Marketing Sentinel
During the last session, electroCore Inc. (NASDAQ:ECOR)’s traded shares were 0.37 million, with the beta value of the company hitting 0.93. At the end of the trading day, the stock’s price was $0.55, reflecting an intraday gain of 5.64% or $0.03. The 52-week high for the ECOR share is $2.44, that puts it down -343.64 … Boom Or Bust? Where Will electroCore Inc. (NASDAQ: ECOR) Stock Go Next? Read More »